Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorNew Valley University

About this trial

Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.

Eligibility criteria

Qualifiers

Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)

Disqualifiers

Patients diagnosed to have type 1 diabetes.

Patients are diagnosed to have secondary diabetes.

Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.

After blood transfusions

Trial design

Treatments tested in this trial

  • Glycated hemoglobin (HbA1C)
  • RDW
  • Lipid profile

Treatment groups

250 Participants
are divided into 2 treatment groups

Sponsors and collaborators